10-Q: Humacyte Narrows Losses, Launches Symvess Amidst Legal Challenges

Humacyte, Inc. reported a significant reduction in net loss and its first product revenue from Symvess sales, while navigating increased cash burn and multiple legal proceedings.

Summary

• Net loss for the nine months ended September 30, 2025, significantly decreased to $16.0 million from $127.8 million in the prior year.
• Generated first product revenue of $0.95 million from U.S. sales of Symvess™ (ATEV) for vascular trauma, with first commercial shipments in March 2025.
• Total revenue for the nine months ended September 30, 2025, was $1.6 million, including $0.6 million from contract revenue.
• Operating losses improved to $77.3 million for the nine months ended September 30, 2025, from $86.3 million in the prior year.
• Net cash used in operating activities increased to $78.9 million for the nine months ended September 30, 2025, compared to $71.5 million in the prior year.
• Cash and cash equivalents stood at $19.5 million as of September 30, 2025, a decrease from $44.9 million at December 31, 2024.
• Implemented a cost reduction action in April 2025, reducing workforce by 30 employees and cutting other operating expenses, projected to save $13.8 million in 2025 and $38.0 million in 2026.
• Amended lease agreements in September 2025, extending the term to March 31, 2037, resetting base rent, and securing two rent abatement periods (Jan-Mar 2026 and Jan-Mar 2027).
• Landlord agreed to forgive $2.76 million in Outstanding TI Rent and $0.19 million in Outstanding CapEx Costs as part of the lease amendment.
• Received $4.5 million Building System Improvement Allowance from the landlord for facility upgrades.
• Made a $50.0 million repayment under the Revenue Interest Purchase Agreement in September 2025, funded from restricted cash, reducing the liability to $20.7 million.
• CMS declined the New Technology Add-On Payment (NTAP) application for Symvess in July 2025, though the company believes the impact on commercial success is limited to 4.3% of Medicare-covered vascular trauma patients.
• Multiple class action and derivative lawsuits have been filed against the company and its officers/directors, alleging false/misleading statements and omissions related to Symvess safety, manufacturing deficiencies, and financial condition.

Sentiment

Score: 6

Explanation: The company achieved its first product revenue and significantly reduced its net loss, indicating progress in commercialization and financial management. Positive clinical trial results and RMAT designations also support future growth. However, increased cash burn from operations, a declining cash balance, and ongoing legal proceedings present significant challenges and risks, necessitating continuous capital raises.

Positives

• Achieved first product revenue of $0.95 million from U.S. sales of Symvess™ for vascular trauma, marking a significant commercial milestone.
• Reported a substantial reduction in net loss for the nine months ended September 30, 2025, to $16.0 million, down from $127.8 million in the prior year.
• Operating losses decreased to $77.3 million for the nine months ended September 30, 2025, from $86.3 million in the same period of 2024.
• Realized significant non-cash gains from the fair value remeasurement of the Contingent Earnout Liability ($49.2 million) and derivative liabilities ($18.2 million).
• Successfully completed the V007 Phase 3 trial for AV access for hemodialysis, meeting primary endpoints.
• Received Regenerative Medicine Advanced Therapy (RMAT) designation for the ATEV for patients with advanced Peripheral Artery Disease (PAD) in June 2024.
• Implemented cost reduction measures expected to save $13.8 million in 2025 and $38.0 million in 2026.
• Secured a lease amendment extending the term to March 31, 2037, including rent abatements and forgiveness of $2.76 million in Outstanding TI Rent and $0.19 million in Outstanding CapEx Costs.
• Received a $4.5 million Building System Improvement Allowance from the landlord for facility upgrades.
• Reduced the revenue interest liability by $50.0 million through a partial call payment, decreasing the obligation to $20.7 million.
• Subsequent to the reporting period, completed a registered direct offering on October 6, 2025, raising approximately $56.5 million in net proceeds.

Negatives

• Net cash used in operating activities increased to $78.9 million for the nine months ended September 30, 2025, from $71.5 million in the prior year, indicating a higher cash burn.
• Cash and cash equivalents decreased significantly to $19.5 million as of September 30, 2025, from $44.9 million at December 31, 2024.
• Working capital decreased to $15.8 million as of September 30, 2025, from $27.9 million at December 31, 2024.
• Accumulated deficit increased to $702.0 million as of September 30, 2025, from $686.0 million at December 31, 2024.
• Selling, general and administrative expenses increased by 28% to $23.6 million for the nine months ended September 30, 2025, primarily due to the commercial launch of Symvess.
• The Centers for Medicare and Medicaid Services (CMS) declined the New Technology Add-On Payment (NTAP) application for Symvess in July 2025.
• The company's future viability beyond the next 12 months is dependent on generating cash flows from Symvess sales and raising additional capital.
• Multiple class action and derivative lawsuits have been filed against the company and its officers/directors, alleging false or misleading statements and omissions.

Risks

• Inability to successfully commercialize Symvess and, if approved, product candidates on anticipated timelines.
• Uncertainty regarding market acceptance and third-party coverage/reimbursement for Symvess and product candidates.
• Challenges in manufacturing Symvess and product candidates in sufficient quantities for clinical and commercial needs.
• Inability to obtain and maintain intellectual property protection or operate without infringing on others' IP rights.
• Dependence on third parties, including manufacturers, licensors, suppliers, and clinical trial organizations.
• Potential for significant additional financial resources and time required if regulatory authorities demand more clinical trials or if there are delays in enrollment/conduct of trials.
• Risk that cost-saving measures may not yield expected benefits or could result in further asset impairment charges, personnel attrition, or reduced employee morale.
• Uncertainty regarding the outcome of ongoing discussions with the FDA concerning clinical trial design.
• Involvement in existing or potential claims and legal/administrative proceedings, which could have a material adverse effect on business, prospects, financial condition, and results of operations.
• Inability to attract, retain, and motivate qualified personnel and manage growth effectively.
• Uncertainty regarding the sufficiency of existing cash and cash equivalents to fund operations beyond 12 months, and the ability to raise additional capital on acceptable terms.
• Impact of the overall global economy, increasing interest rates, and inflation on the business.
• Risk of inventory write-offs if market acceptance of Symvess does not occur or is delayed, prior to shelf-life expiration.

Future Outlook

The company expects to incur substantial operating losses and negative cash flows for the foreseeable future as it commercializes Symvess and advances its product candidates. Future viability beyond 12 months depends on generating cash from Symvess sales and raising additional capital. Plans include submitting a supplemental BLA for AV access for hemodialysis in the second half of 2026, contingent on positive V012 Phase 3 trial results. The company will continue preclinical and clinical development for PAD, CABG, BVP for diabetes, and explore other applications of its technology.

Management Comments

• We believe our regenerative medicine technology has the potential to overcome limitations in existing standards of care and address the lack of significant innovation in products that support tissue repair, reconstruction and replacement.
• We believe that ATEVs have the potential to become the standard of care and lead to improved patient outcomes and lower healthcare costs.
• We believe our cash and cash equivalents on hand and existing capacity under our Common Stock Purchase Agreement will be sufficient to fund operations for at least twelve months from the issuance date of these interim financial statements.
• The future viability of the Company beyond that point is dependent on its ability to generate cash flows from the sale of Symvess and raise additional capital to finance its operations.
• We plan to seek additional funding through private or public equity financings, debt financings, debt refinancings or restructurings, collaborations, strategic alliances, and marketing, distribution or licensing arrangements.
• We believe that the potential impact of the NTAP on commercial success is limited as only approximately 4.3% of vascular trauma patients are covered under Medicare reimbursement.

Industry Context

Humacyte operates in the high-growth, high-risk biotechnology and regenerative medicine sector, focusing on bioengineered human tissues. The commercial launch of Symvess for vascular trauma positions it in a market with existing limitations in autologous vessels and synthetic grafts, where its ATEVs aim to offer superior outcomes. The pursuit of indications in AV access for hemodialysis and PAD aligns with significant unmet medical needs in chronic disease management. The company's reliance on equity and debt financing, coupled with substantial R&D expenses and operating losses, is typical for early-stage biotech firms developing novel therapies. The decline of the NTAP application by CMS highlights the challenges of securing favorable reimbursement for innovative medical technologies, a common hurdle in the industry.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct benchmarking.
• However, the company's accumulated deficit of $702.0 million and continued operating losses are common for biotechnology companies in the development and early commercialization stages, which require extensive capital for R&D and clinical trials.
• The successful completion of a Phase 3 trial (V007) and FDA approval for Symvess are significant milestones, placing Humacyte among a select group of biotech firms that have brought a novel regenerative medicine product to market.
• The ongoing need for capital raises, as evidenced by the subsequent registered direct offering, is standard practice for biotech companies to fund continued R&D, commercialization, and pipeline expansion.
• The legal challenges faced by the company, including class action and derivative lawsuits, are not uncommon in the highly scrutinized pharmaceutical and biotech industries, particularly for companies with new product approvals and public offerings.

Corporate Governance

Legal Proceedings

• Securities Litigation (Cutshall v. Humacyte, Inc., et al.): Class action lawsuit filed November 18, 2024, alleging false/misleading statements and omissions related to BLA for vascular trauma, alleged deficiencies at Durham manufacturing facility, Symvess safety, and financial condition/liquidity. Amended complaint filed May 22, 2025, expanding class period. Defendants moved to dismiss on July 25, 2025.
• Consolidated Derivative Action (Silva v. Sebelius, et al. and Misko v. Niklason, et al.): Two derivative actions filed January 7 and 10, 2025, consolidated February 18, 2025, alleging violations of Section 14(a) of the Exchange Act, breach of fiduciary duty, unjust enrichment, abuse of control, gross mismanagement, and waste of corporate assets. Stayed pending final resolution of the Securities Litigation.
• Olson Action (Olson v. Niklason, et al.): Stockholder derivative action filed February 19, 2025, alleging similar claims to the Consolidated Derivative Action, after a demand letter was sent on December 19, 2024. Stayed pending final resolution of the Securities Litigation.
• Dusci Action (Dusci v. Bamforth, et al.): Stockholder derivative action filed June 9, 2025, alleging similar claims to the Consolidated Derivative Action and Olson Action. Stayed pending final resolution of the Securities Litigation.
• 2025 Demand Letter: Received May 19, 2025, making demands and allegations similar to the 2024 Demand Letter. Board deferred action pending resolution of the motion to dismiss in the securities class action.
• The company disputes all claims and is currently unable to estimate potential loss, deeming a negative outcome not probable and no material liabilities accrued as of September 30, 2025.

Related Party Transactions

• Fresenius Medical Care: Purchased 15,812,735 shares of Common Stock in June 2018 and an additional 2.5 million shares in August 2021. Has a distribution agreement for the company's 6mm x 42cm ATEV outside the U.S. and EU, and collaboration within the U.S. The company is obligated to make revenue-share payments based on U.S. net sales. Fresenius Medical Care Deutschland GmbH provides medical scientific research services through Frenova Renal Research. $0.1 million in royalties payable to Fresenius Medical Care as of September 30, 2025.
• Yale University: The company's President and CEO, Laura Niklason M.D., PhD., serves as an Adjunct Professor at Yale University. The company has license agreements with Yale for biovascular pancreas (BVP) product candidate and tubular prostheses. Payments to Yale under license agreements were immaterial during the periods presented.

Stakeholder Impact

• Shareholders: Potential for dilution from ongoing and future equity raises. Share price could be significantly influenced by clinical trial results, regulatory approvals, commercial success of Symvess, and outcomes of legal proceedings. The increase in authorized shares provides flexibility for future capital raises but also potential dilution.
• Employees: Workforce reduction of 30 employees in April 2025 impacted personnel. The reduction in ESPP shares may affect employee incentives.
• Customers: Availability of Symvess for vascular trauma patients in the U.S. provides a new treatment option. Future product candidates (AV access, PAD) could further benefit patients.
• Creditors: The $50.0 million repayment on the Revenue Interest Purchase Agreement reduces debt obligations, improving the company's financial position relative to this specific creditor.
• Suppliers: Continued R&D and manufacturing activities will maintain demand for materials and services.

Next Steps

• Continue commercialization of Symvess in the U.S. for vascular trauma.
• Seek marketing approval for Symvess in additional indications and for product candidates in the U.S.
• Obtain marketing approval for 6mm ATEV outside the U.S.
• Continue clinical development of 6mm ATEV for hemodialysis AV access.
• Submit a supplemental BLA for FDA approval of an indication in AV access for hemodialysis in H2 2026, contingent on positive V012 Phase 3 trial results.
• Advance pipeline in major markets, including PAD Phase 3 trials.
• Continue preclinical development and advance to planned clinical studies in CABG and BVP for diabetes.
• Expand manufacturing facility as required to satisfy market demand.
• Engage in discussions with CMS regarding the declined NTAP application for Symvess.
• Evaluate claims made in the 2025 Demand Letter by the demand evaluation committee.
• Seek additional funding through various financing and strategic arrangements.

Key Dates

Recommendation

Humacyte has achieved a critical milestone with the commercial launch of Symvess and reported a substantial reduction in net loss, demonstrating progress in its core business. Positive Phase 3 trial results for AV access also signal potential for pipeline expansion. However, the company continues to burn significant cash from operations, leading to a weakened cash position and ongoing reliance on capital raises, as evidenced by the recent registered direct offering. The decline of the NTAP application by CMS, while deemed limited in impact by management, could still affect reimbursement. Furthermore, multiple pending legal proceedings introduce considerable uncertainty and potential financial liabilities. Given the early commercial stage, high capital requirements, and legal overhang, a 'hold' recommendation is appropriate. Investors should monitor commercial uptake of Symvess, progress in clinical trials, resolution of legal matters, and the company's ability to secure additional non-dilutive funding.

Keywords

Humacyte, Symvess, ATEV, Vascular Trauma, Biotechnology, Regenerative Medicine, SEC Filing, 10-Q, Clinical Trials, FDA Approval, AV Access, PAD, Financial Results, Liquidity, Capital Raise, Legal Proceedings, Medical Devices